Pharsight

Finacea generic

Finacea is a topical treatment for inflammatory papules and pustules of mild to moderate rosacea, owned by Leo Pharma As. The drug, which contains the active ingredient azelaic acid, was first authorized for market use on 29 July, 2015.

When will Finacea generic be available?

The generic version of Finacea can possibly be released after the last patent expires on 28 February, 2029. This is majorly due to the expiration of the patent titled 'Antibiotic kit and composition and uses thereof'.

Finacea uses

Finacea, with its active ingredient azelaic acid, is primarily used as a topical treatment for inflammatory papules and pustules of mild to moderate rosacea.

Finacea patent expiration

Finacea holds a total of 8 drug patents, 3 of which have already expired. The last of the remaining patents, titled 'Antibiotic kit and composition and uses thereof' under the number US9211259, will expire on 28 February, 2029, paving the possible path for Finacea generic. Below are the details of the patent:

EPO Oppostions filed on Finacea

Finacea dosage

Want to ask something?